gdc
Multiple MyelomaSlideshows

Multiple Myeloma

March is multiple myeloma month. Check out our slideshow on this cancer type.
Web Exclusives – March 28, 2017

  • Centers For Disease Control Co 768x512

    March is Multiple Myeloma Awareness Month. Here are some risk factors and statistics related to the disease.

  • Diverse Group 768x512

    In 2017, an estimated 30,280 new cases of multiple myeloma will be diagnosed, including 17,490 men and 12,790 women.

    Source: The American Cancer Society
  • Senior Couple On Bicycles 768x512

    Multiple myeloma is more than twice as common in African Americans as in white Americans.

    Source: The American Cancer Society
  • Mother Grown Son 768x512

    People who have a sibling or parent with multiple myeloma are 4 times more likely to have the disease.

    Source: The American Cancer Society
  • Mm Cells 768x512

    This disease is the second most common blood cancer in the world.

    Source: International Myeloma Foundation
  • Cq Logo

    To read more about multiple myeloma, check out our articles here.  

Share this:

Recommended For You
FDA Approvals, News & UpdatesMultiple Myeloma
FDA Approves Abecma, First CAR T-Cell Therapy for Multiple Myeloma
Abecma is the first gene therapy approved by the FDA for patients with multiple myeloma. It uses the patient’s own genetically modified T-cells to fight the cancer.
FDA Approvals, News & UpdatesMultiple Myeloma
FDA Approved Pepaxto for Relapsed or Refractory Multiple Myeloma
Pepaxto is a novel therapy that has shown good results in multiple myeloma that does not respond to other therapies, according to myeloma expert Paul G. Richardson, MD, of Dana-Farber Cancer Institute.
Oral HealthTransplantsLymphomaLeukemiaMultiple Myeloma
Bone Marrow Transplants and Oral Health for Patients with Blood Cancers
By Jill Meyer-Lippert, RDH, Amanda Swiecichowski, RN, BSN, CHPN
Two oral health experts offer a thorough exploration of bone marrow transplants and how they relate to the mouth, with many tips for maintaining proper oral care during and after a transplant.
FDA Approvals, News & UpdatesMultiple Myeloma
Xpovio Approved for Patients with Relapsed or Refractory Multiple Myeloma
In December 2020, the FDA approved Xpovio (selinexor), for use in combination with the proteasome inhibitor Velcade (bortezomib) and the steroid dexamethasone, for the treatment of adults with multiple myeloma who have received at least 1 previous therapy. Xpovio was previously approved for several types of lymphoma.
Last modified: October 3, 2017

Subscribe to CONQUER: the patient voice magazine

Receive timely cancer news & updates, patient stories, and more.

Country